4CPS-181 Study of the reasons for the therapeutic discontinuation of immune-based therapies in relapsing-remitting multiple sclerosis

BACKGROUND: Nowadays, 12 different therapies are available as immune-mediated therapies (IMT) for multiple sclerosis (MS) drugs. Guidelines classify these treatments as first- and second-line. This variety allows treatment discontinuations (TD) under situations different from those initially planned...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur J Hosp Pharm
Main Authors: Rubio, S Marín, Font, M Miarons, Cordón, L Pérez, Ulayar, A Sanchez, Bernadas, L Campins, Maragall, C Agustí, Ferrer, M Camps, Roig, T Gurrera, Faixo, D Lopez
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Group 2018
Fag:
Section 4: Clinical pharmacy services
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535331/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.271
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker